PsiThera raises $25m to advance oral TNFα and TL1A drugs
AbbVie Ventures joins existing investors in financing to support development of oral immunology treatments
PsiThera has raised $25 million to advance its oral TNFα inhibitor towards development candidate nomination and move its TL1A programme into lead optimisation.
The financing brings new investors AbbVie Ventures and Lumination Capital into the Massachusetts-based biotechnology company, alongside existing investors Samsara BioCapital and Lightstone Ventures. Claire Leurent, managing director at AbbVie Ventures, has also joined PsiThera’s board of directors.
The proceeds will support development of PsiThera’s lead oral small-molecule TNFα inhibitor, including the initiation of investigational new drug (IND)-enabling studies. The company also plans to advance its oral TL1A programme into lead optimisation.
Both targets are associated with inflammatory and immune-mediated diseases, where injectable biologic medicines have become established treatment options.
Oral alternatives to injectable biologics
TNFα is an established target in immunology, with injectable anti-TNFα biologics approved across a range of immune-mediated conditions. PsiThera is developing small-molecule inhibitors that could offer an oral alternative.
The company said its oral TNFα inhibitors are designed to achieve a differentiated therapeutic profile compared with injectable treatments and other oral TNFα inhibitors in development.
An oral treatment could potentially offer another option for patients who have not started biologic therapy, as well as providing opportunities for combination treatment.
PsiThera’s chief executive officer Eric Shaff said: “Our goal is to bring the efficacy of leading biologics into novel oral medicines to improve on their therapeutic profiles. This financing accelerates our progress toward that vision as we advance our oral TNFα program toward development candidate nomination and clinical initiation and expand our pipeline of differentiated immunology therapeutics, starting with TL1A.”
The company has not yet announced clinical data for its programmes. Its immediate focus is on progressing the TNFα candidate through preclinical development and preparing for




